Chris Pierzchalski

Clinical Research

[Galaxy Therapeutics @GalaxyThera]

Our latest peer-reviewed study in @FrontNeurol compares SEAL™ and WEB™ using advanced PIV flow analysis.

SEAL™ demonstrated greater flow disruption in this aneurysm model, contributing to the growing body of evidence supporting the platform.

https://t.co/ErgeY9SlIq

[Chris Pierzchalski @chrispy011]

Excited to share MEMBRANE primary results published. TRUFILL for cSDH

[JAMA Neurology @JAMANeuro]

Randomized clinical trial indicates middle meningeal artery embolization with n-butyl cyanoacrylate plus standard care reduced #SubduralHematoma recurrence and need for surgery vs standard care alone, with comparable safety profile.

https://t.co/3MZBptUzg1

[JAMA Neurology @JAMANeuro]

Randomized clinical trial indicates middle meningeal artery embolization with n-butyl cyanoacrylate plus standard care reduced #SubduralHematoma recurrence and need for surgery vs standard care alone, with comparable safety profile.

https://t.co/3MZBptUzg1

[Chris Pierzchalski @chrispy011]

@GalaxyThera @oozaidat Congrats @oozaidat and everyone involved. Huge accomplishment by a great team.

[Galaxy Therapeutics @GalaxyThera]

Press Release: Enrollment completed in SEAL IT IDE Trial

279 patients | 50 centers | WNBA, Sidewall & Ruptured cohorts

https://t.co/jMDeEdmS8e

#SEALIT #GalaxyTherapeutics #Neurointervention #FDAIDE

[NeuroNews @NN_publishing]

Today, @JNJMedTech announced that the @US_FDA has approved an expanded indication for its Trufill n‑BCA liquid embolic system covering MMA embolisation as a surgical adjunct in the treatment of symptomatic subacute and chronic SDH
@chriskellnerMD @JNJNews
https://t.co/RmKXARmSiD

[Galaxy Therapeutics @GalaxyThera]

The SEAL IT IDE Trial has completed patient enrollment.

Final patient enrolled today by Dr. Demetrius Lopes and the Aurora Lutheran team — just over 16 months after study initiation.

A milestone built by an entire community.

#SEALIT #IDEtrial #Neurointervention

[NEJM @NEJM]

Presented at #SVIN25:

CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: https://t.co/ojge1CjqiU

Editorial: Managing Asymptomatic Carotid Stenosis https://t.co/D9LH89Edyk

@svinsociety

[Chris Pierzchalski @chrispy011]

@ShashvatDesai @GravityMedTech @AshuPJadhav @KunakornAt @JayDoliaMD @dyavagal @TudorGJovin @MoHFW_INDIA @suresh8ir @PMOIndia Congratulations shashvat and everyone else! Amazing work

[UofL Neurosurgery @UofLNeurosurg]

"It is cutting edge & it was so easy for me."

The first patient in Kentucky to enroll in a new clinical trial for brain aneurysms sat down with Dr. Josh Abecassis & @spectrumnews1ky to talk about the surgery & the device.
https://t.co/qPob17bIU4

@drjoshabecassis @GalaxyThera

[Galaxy Therapeutics @GalaxyThera]

WNBA enrollment completed! 🎯
163 patients in 10 months — milestone reached at Jefferson Health by Dr. Tjoumakaris (proctored by Dr. Altschul).

Recruitment continues for sidewall & ruptured aneurysms.

#SEALIT #GalaxyTherapeutics #Neurointervention

[Galaxy Therapeutics @GalaxyThera]

🌍 Galaxy Therapeutics Update 🌍

A major milestone! 🚀 The SEAL ARC 20x16 device was used for the first time in the US at St. David’s Medical Center by Dr. James.

Pushing the boundaries of neurointervention—thank you to the team for their expertise! 👏

[Galaxy Therapeutics @GalaxyThera]

🌍 SEAL IT IDE Trial Update 🌍

We’ve reached a key milestone—100 enrolled patients! 🎉

A huge thank you to all our enrolling sites & investigators for their dedication. Special acknowledgment to Prof. Adnan Siddiqui (University at Buffalo, NY) for enrolling patient #100!

[Galaxy Therapeutics @GalaxyThera]

🌍 SEAL IT IDE Update 🌍 9 new enrollments (95 total), 5 in 1 day! Thanks to Drs. Dabus (Baptist Miami), Young & Lopes (Advocate Lutheran), Aghaebrahim & Hanel (Baptist Health), Kass-Hout (UChicago), Boo (WVU), Dandapat (Advocate St. Luke’s)! #SEALIT 🚀

[Galaxy Therapeutics @GalaxyThera]

🌍 SEAL IT IDE Trial Update 🌍

A new enrolling center! HCA Kingwood, Houston, TX, joins the SEAL IT trial, led by Dr. Mohamad Ezzeldin. Excited to see this study grow!

#SEALITTrial #Neurointervention #BrainAneurysm #GalaxyTherapeutics

[Chris Pierzchalski @chrispy011]

@visishs @Stryker_NV @cvsection @SNISinfo @YoungNIR #JustSEALIT the Galaxy SEAL ARC is designed to conform to the aneurysm shape and stay - (investigational use in the US) - case is a courtesy of @DanTonettiMD

[Galaxy Therapeutics @GalaxyThera]

🌍 SEAL IT IDE Trial Update 🌍
Cleveland Clinic hits 10 enrollments, the site that leads the SEAL IT trial!

Today’s 70th case was enrolled by Dr. Shazam Hussain, with contributions this week from Dr. Ashutosh Mahapatra.

Thank you, Cleveland Clinic team!

#SEALIT #Galaxy

[Galaxy Therapeutics @GalaxyThera]

🌍 SEAL IT IDE Trial Update 🌍
4th case of 2025 completed at TSI, Texas, by Dr. Bhuva and team.

Advancing innovation in neurointervention—one case at a time.

#Neurointervention #MedicalInnovation #ClinicalTrials #GalaxyTherapeutics

[Galaxy Therapeutics @GalaxyThera]

🌍 SEAL IT IDE Trial update 🌍

2 new patients have been enrolled in our SEAL IT IDE trial at Cooper University Hospital. Grateful to Dr. Daniel Tonetti and his team for their dedication. Each step advances our shared knowledge in aneurysm treatment. Stay tuned for more updates!

[Adnan H. Siddiqui, MD @_AdnanSiddiqui]

Leo Nelson (Nick) Hopkins passed last night at the place he imagined and created, the #GatesVascularInstitute in #Buffalo, New York.

On behalf of all the members of the @JacobsInstitute and the Canon #Stroke and #Vascular Research Center, we send our most sincere wishes to Bonnie, Jane, Bob, Margie and Betsy and their kids, and express our enduring commitment to live out the vision of Dr. Hopkins and honor his legacy of genuine collaboration, inventive spirit, and humble leadership.

@UBuffalo @KaleidaHealth @Jacobs_Med_UB #neurosurgery #endovascular